Your browser doesn't support javascript.
loading
Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using 68Ga-DOTATATE, FDG, 18F-FDOPA, and 18F-FDA).
Jha, Abhishek; Patel, Mayank; Carrasquillo, Jorge A; Ling, Alexander; Millo, Corina; Saboury, Babak; Chen, Clara C; Wakim, Paul; Gonzales, Melissa K; Meuter, Leah; Knue, Marianne; Talvacchio, Sara; Herscovitch, Peter; Rivero, Jaydira Del; Chen, Alice P; Nilubol, Naris; Taïeb, David; Lin, Frank I; Civelek, Ali Cahid; Pacak, Karel.
Afiliación
  • Jha A; Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bldg 10, CRC, Rm 1E-3140, 10 Center Dr, MSC-1109, Bethesda, MD 20892-1109.
  • Patel M; Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bldg 10, CRC, Rm 1E-3140, 10 Center Dr, MSC-1109, Bethesda, MD 20892-1109.
  • Carrasquillo JA; Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Ling A; Targeted Radionuclide Therapy Section, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Millo C; Radiology and Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD.
  • Saboury B; PET Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD.
  • Chen CC; Radiology and Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD.
  • Wakim P; Radiology and Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD.
  • Gonzales MK; Biostatistics and Clinical Epidemiological Service, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD.
  • Meuter L; Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bldg 10, CRC, Rm 1E-3140, 10 Center Dr, MSC-1109, Bethesda, MD 20892-1109.
  • Knue M; Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bldg 10, CRC, Rm 1E-3140, 10 Center Dr, MSC-1109, Bethesda, MD 20892-1109.
  • Talvacchio S; Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bldg 10, CRC, Rm 1E-3140, 10 Center Dr, MSC-1109, Bethesda, MD 20892-1109.
  • Herscovitch P; Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bldg 10, CRC, Rm 1E-3140, 10 Center Dr, MSC-1109, Bethesda, MD 20892-1109.
  • Rivero JD; PET Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD.
  • Chen AP; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Nilubol N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Taïeb D; Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Lin FI; Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France.
  • Civelek AC; Targeted Radionuclide Therapy Section, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Pacak K; Radiology and Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD.
AJR Am J Roentgenol ; 218(2): 342-350, 2022 02.
Article en En | MEDLINE | ID: mdl-34431366
ABSTRACT
BACKGROUND. Recent professional society guidelines for radionuclide imaging of sporadic pheochromocytoma (PHEO) recommend 18F-fluorodihydroxyphenylala-nine (18F-FDOPA) as the radiotracer of choice, deeming 68Ga-DOTATATE and FDG to be second- and third-line agents, respectively. An additional agent, 18F-fluorodopamine (18F-FDA), remains experimental for PHEO detection. A paucity of research has performed head-to-head comparison among these agents. OBJECTIVE. The purpose of this study was to perform an intraindividual comparison of 68Ga-DOTATATE PET/CT, FDG PET/CT, 18F-FDOPA PET/CT, 18F-FDA PET/CT, CT, and MRI in visualization of sporadic primary PHEO. METHODS. This prospective study enrolled patients referred with clinical suspicion for sporadic PHEO. Patients were scheduled for 68Ga-DOTATATE PET/CT, FDG PET/CT, 18F-FDOPA PET/CT, 18F-FDA PET/CT, whole-body staging CT (portal venous phase), and MRI within a 3-month period. PET/CT examinations were reviewed by two nuclear medicine physicians, and CT and MRI were reviewed by two radiologists; differences were resolved by consensus. Readers scored lesions in terms of confidence in diagnosis of PHEO (1-5 scale; 4-5 considered positive for PHEO). Lesion-to-liver SUVmax was computed using both readers' measurements. Interreader agreement was assessed using intraclass correlation coefficients (ICCs) for SUVmax. Analysis included only patients with histologically confirmed PHEO on resection. RESULTS. The analysis included 14 patients (eight women, six men; mean age, 52.4 ± 16.8 [SD] years) with PHEO. Both 68Ga-DOTATATE PET/CT and FDG PET/CT were completed in all 14 patients, 18F-FDOPA PET/CT in 11, 18F-FDA PET/CT in 7, CT in 12, and MRI in 12. Mean conspicuity score for PHEO was 5.0 ± 0.0 for 18F-FDOPA PET/CT, 4.7 ± 0.5 for MRI, 4.6 ± 0.8 for 18F-FDA PET/CT, 4.4 ± 1.0 for 68Ga-DOTATATE PET/CT, 4.3 ± 1.0 for CT, and 4.1 ± 1.5 for FDG PET/CT. The positivity rate for PHEO was 100.0% (11/11) for 18F-FDOPA PET/CT, 100.0% (12/12) for MRI, 85.7% (6/7) for 18F-FDA PET/CT, 78.6% (11/14) for FDG PET/CT, 78.6% (11/14) for 68Ga-DOTATATE PET/CT, and 66.7% (8/12) for CT. Lesion-to-liver SUVmax was 10.5 for 18F-FDOPA versus 3.0-4.2 for the other tracers. Interreader agreement across modalities ranged from 85.7% to 100.0% for lesion positivity with ICCs of 0.55-1.00 for SUVmax measurements. CONCLUSION. Findings from this small intraindividual comparative study support 18F-FDOPA PET/CT as a preferred first-line imaging modality in evaluation of sporadic PHEO. CLINICAL IMPACT. This study provides data supporting current guidelines for imaging evaluation of suspected PHEO. TRIAL REGISTRATION. ClinicalTrials.gov NCT00004847.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Feocromocitoma / Imagen por Resonancia Magnética / Neoplasias de las Glándulas Suprarrenales / Radiofármacos / Fluorodesoxiglucosa F18 / Tomografía Computarizada por Tomografía de Emisión de Positrones / Radioisótopos de Galio Tipo de estudio: Guideline / Observational_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: AJR Am J Roentgenol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Feocromocitoma / Imagen por Resonancia Magnética / Neoplasias de las Glándulas Suprarrenales / Radiofármacos / Fluorodesoxiglucosa F18 / Tomografía Computarizada por Tomografía de Emisión de Positrones / Radioisótopos de Galio Tipo de estudio: Guideline / Observational_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: AJR Am J Roentgenol Año: 2022 Tipo del documento: Article